Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 22 | 2024 | 3226 | 2.530 |
Why?
|
| Pulmonary Emphysema | 5 | 2024 | 688 | 1.430 |
Why?
|
| Eosinophils | 2 | 2018 | 944 | 0.870 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 3 | 2023 | 502 | 0.850 |
Why?
|
| Lung | 13 | 2024 | 9994 | 0.760 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2019 | 78 | 0.650 |
Why?
|
| Respiration Disorders | 1 | 2022 | 368 | 0.640 |
Why?
|
| Forced Expiratory Volume | 3 | 2022 | 1809 | 0.630 |
Why?
|
| Lymphocytes | 1 | 2021 | 2611 | 0.440 |
Why?
|
| Membrane Glycoproteins | 2 | 2021 | 3709 | 0.420 |
Why?
|
| Emphysema | 4 | 2024 | 240 | 0.380 |
Why?
|
| Carrier Proteins | 2 | 2021 | 4938 | 0.360 |
Why?
|
| Gene Expression Profiling | 5 | 2024 | 9406 | 0.330 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2007 | 52 | 0.290 |
Why?
|
| RNA Viruses | 1 | 2008 | 110 | 0.290 |
Why?
|
| Gene Expression Regulation | 3 | 2022 | 11902 | 0.270 |
Why?
|
| Leukocyte Count | 3 | 2018 | 1599 | 0.260 |
Why?
|
| Vitamin B Complex | 1 | 2007 | 297 | 0.250 |
Why?
|
| alpha 1-Antitrypsin | 2 | 2024 | 169 | 0.240 |
Why?
|
| BCG Vaccine | 1 | 2007 | 371 | 0.240 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2021 | 812 | 0.240 |
Why?
|
| Vitamin A | 1 | 2007 | 613 | 0.230 |
Why?
|
| Smoking | 4 | 2021 | 9073 | 0.230 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2024 | 113 | 0.220 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2023 | 188 | 0.210 |
Why?
|
| Inflammation | 2 | 2023 | 10755 | 0.210 |
Why?
|
| Folic Acid | 1 | 2007 | 1309 | 0.180 |
Why?
|
| Desmoplakins | 1 | 2020 | 62 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 4550 | 0.170 |
Why?
|
| Vitamins | 1 | 2007 | 1634 | 0.160 |
Why?
|
| Interferons | 1 | 2022 | 705 | 0.160 |
Why?
|
| GTPase-Activating Proteins | 1 | 2021 | 475 | 0.150 |
Why?
|
| Genome-Wide Association Study | 4 | 2021 | 12628 | 0.150 |
Why?
|
| Disease Progression | 5 | 2023 | 13505 | 0.150 |
Why?
|
| F-Box Proteins | 1 | 2019 | 202 | 0.150 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 469 | 0.150 |
Why?
|
| Xenobiotics | 1 | 2017 | 70 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 3484 | 0.140 |
Why?
|
| Genotype | 2 | 2022 | 12957 | 0.140 |
Why?
|
| Adenoma | 1 | 2007 | 2148 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 3 | 2022 | 2005 | 0.140 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 608 | 0.140 |
Why?
|
| Phenotype | 5 | 2022 | 16548 | 0.140 |
Why?
|
| Exons | 2 | 2019 | 2389 | 0.120 |
Why?
|
| Heterozygote | 1 | 2022 | 2798 | 0.120 |
Why?
|
| RNA | 2 | 2023 | 2723 | 0.120 |
Why?
|
| Spirometry | 1 | 2018 | 924 | 0.120 |
Why?
|
| Signal Transduction | 2 | 2017 | 23374 | 0.120 |
Why?
|
| Haploinsufficiency | 1 | 2016 | 329 | 0.120 |
Why?
|
| Alternative Splicing | 1 | 2019 | 1091 | 0.110 |
Why?
|
| RNA, Untranslated | 1 | 2017 | 459 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2022 | 17790 | 0.110 |
Why?
|
| Gene Expression | 3 | 2021 | 7587 | 0.110 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 2380 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2018 | 726 | 0.110 |
Why?
|
| Humans | 33 | 2024 | 760613 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2023 | 1579 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2023 | 18137 | 0.100 |
Why?
|
| Respiratory Function Tests | 3 | 2022 | 1683 | 0.100 |
Why?
|
| Mice, Knockout | 3 | 2021 | 14374 | 0.100 |
Why?
|
| Immunity, Innate | 2 | 2018 | 3047 | 0.100 |
Why?
|
| Fibroblasts | 1 | 2021 | 4089 | 0.090 |
Why?
|
| Leukocytes | 1 | 2018 | 2027 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 4 | 2021 | 22020 | 0.080 |
Why?
|
| Endocarditis, Bacterial | 1 | 2013 | 445 | 0.080 |
Why?
|
| Venous Thromboembolism | 2 | 2014 | 1864 | 0.080 |
Why?
|
| Endocarditis | 1 | 2013 | 351 | 0.080 |
Why?
|
| Renin-Angiotensin System | 1 | 2014 | 738 | 0.080 |
Why?
|
| Oxidative Stress | 2 | 2017 | 3106 | 0.080 |
Why?
|
| Oxygen | 2 | 2018 | 4193 | 0.080 |
Why?
|
| Stem Cells | 1 | 2021 | 3524 | 0.080 |
Why?
|
| Gambia | 1 | 2007 | 104 | 0.070 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 2716 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 6853 | 0.070 |
Why?
|
| Sepsis | 1 | 2021 | 2592 | 0.070 |
Why?
|
| Aged | 12 | 2022 | 169143 | 0.070 |
Why?
|
| Animals | 9 | 2023 | 167960 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 358 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2017 | 3442 | 0.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 1523 | 0.070 |
Why?
|
| Asthma | 2 | 2021 | 6172 | 0.070 |
Why?
|
| Tachycardia, Ventricular | 1 | 2015 | 1303 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2019 | 9288 | 0.070 |
Why?
|
| Mice | 6 | 2023 | 81209 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 14494 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2021 | 18955 | 0.060 |
Why?
|
| Male | 16 | 2022 | 359718 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2020 | 6552 | 0.060 |
Why?
|
| Middle Aged | 11 | 2022 | 220359 | 0.060 |
Why?
|
| Morphogenesis | 1 | 2008 | 740 | 0.060 |
Why?
|
| Female | 15 | 2022 | 391246 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2007 | 1428 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2008 | 720 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2015 | 6415 | 0.050 |
Why?
|
| Atherosclerosis | 2 | 2014 | 3518 | 0.040 |
Why?
|
| Hypertension, Pulmonary | 2 | 2008 | 1570 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2022 | 24102 | 0.040 |
Why?
|
| Proteomics | 2 | 2024 | 3817 | 0.040 |
Why?
|
| Arylsulfotransferase | 1 | 2019 | 28 | 0.040 |
Why?
|
| Aged, 80 and over | 6 | 2022 | 58980 | 0.040 |
Why?
|
| Aspirin | 2 | 2011 | 3364 | 0.040 |
Why?
|
| Mutation | 1 | 2023 | 29957 | 0.040 |
Why?
|
| Myocardial Infarction | 3 | 2015 | 11890 | 0.040 |
Why?
|
| Neoplasms | 1 | 2007 | 22075 | 0.040 |
Why?
|
| Sex Factors | 2 | 2013 | 10546 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 2282 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2007 | 1915 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 1075 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2021 | 1376 | 0.030 |
Why?
|
| HIV Infections | 1 | 2023 | 17165 | 0.030 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2016 | 100 | 0.030 |
Why?
|
| Lung Compliance | 1 | 2016 | 201 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3332 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2019 | 656 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2023 | 1334 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2022 | 2609 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2008 | 3539 | 0.030 |
Why?
|
| Risk | 1 | 2007 | 9632 | 0.030 |
Why?
|
| Acetylcysteine | 1 | 2016 | 264 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1792 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 2536 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2023 | 2838 | 0.030 |
Why?
|
| Glutathione | 1 | 2016 | 582 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2022 | 15286 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2022 | 1365 | 0.030 |
Why?
|
| Philadelphia | 1 | 2013 | 265 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 1447 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2019 | 2698 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2022 | 15840 | 0.020 |
Why?
|
| Models, Biological | 1 | 2008 | 9468 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 2101 | 0.020 |
Why?
|
| Risk Factors | 3 | 2022 | 74333 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2007 | 26179 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2022 | 9716 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2022 | 10185 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2020 | 3663 | 0.020 |
Why?
|
| Age Factors | 2 | 2016 | 18413 | 0.020 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2008 | 221 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2023 | 54306 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2007 | 193 | 0.020 |
Why?
|
| Cerebral Infarction | 1 | 2011 | 982 | 0.020 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2007 | 378 | 0.020 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2007 | 227 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2011 | 895 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 3527 | 0.020 |
Why?
|
| Infant | 1 | 2007 | 36053 | 0.020 |
Why?
|
| Pulmonary Circulation | 1 | 2007 | 743 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 1109 | 0.020 |
Why?
|
| Incidence | 2 | 2013 | 21391 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2022 | 22052 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 2754 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2013 | 2608 | 0.010 |
Why?
|
| Genomics | 1 | 2018 | 5795 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2022 | 12102 | 0.010 |
Why?
|
| Telomere | 1 | 2008 | 934 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 6498 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6544 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2008 | 2209 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2014 | 3127 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 39262 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 15790 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2013 | 5418 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 10826 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2011 | 3200 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 2543 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 29661 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 12531 | 0.010 |
Why?
|
| Time Factors | 1 | 2018 | 40139 | 0.010 |
Why?
|
| Adult | 2 | 2022 | 220007 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2014 | 80345 | 0.010 |
Why?
|
| Stroke | 1 | 2014 | 9952 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 25941 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 41337 | 0.000 |
Why?
|
Concepts
(173)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(42)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_